Scholarlink

<p>DXd, a camptothecin derivative, is employed as the payload molecule for the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd), which is in current clinical use for the treatment of breast and gastric cancer. Despite the clinical success of ADCs for treatment of cancer, exposure to released payload in plasma and extracellular fluids contributes to off-target toxicities, which limit ADC dosage and efficacy. In this study, we evaluated an anti-DXd antibody fragment, 8C2 Fab, for utility in mitigating DXd toxicity in cell culture and for improving the therapeutic index of T-DXd <i>in vivo</i> in mice. 8C2 Fab was produced, purified, and characterized for binding to DXd and T-DXd. <i>In vitro</i> competitive cytotoxicity assays showed that 8C2 Fab blocked the cell-killing effect of DXd, increasing the DXd concentration associated with 50% growth inhibition (IC<sub>50</sub>) by 50-fold; however, 8C2 did not decrease the cytotoxicity of T-DXd. Co-administration of 8C2 Fab to mice with 600&#xa0;mg/kg T-DXd significantly decreased the percentage body weight loss at nadir in mice compared to results found with T-DXd alone (12.8 ± 3.66% <i>vs</i> 7.08 ± 4.24%, <i>p</i> = 0.0331). In contrast, co-administration of 8C2 Fab with T-DXd (1 or 10&#xa0;mg/kg) did not negatively impact the anti-tumor efficacy in mice bearing NCI-N87 xenograft tumors. Our results demonstrate that 8C2 Fab decreases DXd cytotoxicity <i>in vitro</i>, and decreases T-DXd-induced toxicity <i>in vivo</i>, while not inhibiting T-DXd anti-tumor efficacy <i>in vitro</i> or <i>in vivo</i>, supporting utility for improving the therapeutic index of T-DXd.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Jue Gong,
  • Brandon M. Bordeau,
  • Joseph P. Balthasar

摘要

DXd, a camptothecin derivative, is employed as the payload molecule for the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd), which is in current clinical use for the treatment of breast and gastric cancer. Despite the clinical success of ADCs for treatment of cancer, exposure to released payload in plasma and extracellular fluids contributes to off-target toxicities, which limit ADC dosage and efficacy. In this study, we evaluated an anti-DXd antibody fragment, 8C2 Fab, for utility in mitigating DXd toxicity in cell culture and for improving the therapeutic index of T-DXd in vivo in mice. 8C2 Fab was produced, purified, and characterized for binding to DXd and T-DXd. In vitro competitive cytotoxicity assays showed that 8C2 Fab blocked the cell-killing effect of DXd, increasing the DXd concentration associated with 50% growth inhibition (IC50) by 50-fold; however, 8C2 did not decrease the cytotoxicity of T-DXd. Co-administration of 8C2 Fab to mice with 600 mg/kg T-DXd significantly decreased the percentage body weight loss at nadir in mice compared to results found with T-DXd alone (12.8 ± 3.66% vs 7.08 ± 4.24%, p = 0.0331). In contrast, co-administration of 8C2 Fab with T-DXd (1 or 10 mg/kg) did not negatively impact the anti-tumor efficacy in mice bearing NCI-N87 xenograft tumors. Our results demonstrate that 8C2 Fab decreases DXd cytotoxicity in vitro, and decreases T-DXd-induced toxicity in vivo, while not inhibiting T-DXd anti-tumor efficacy in vitro or in vivo, supporting utility for improving the therapeutic index of T-DXd.

Graphical Abstract